title: Vasculitis syndromes: RAVE about rituximab in ANCA vasculitis?
abstract: Follow-up data from the RAVE trial have shown that rituximab is as effective as immunosuppression with cyclophosphamide followed by azathioprine in antineutrophil cytoplasmic antibody (ANCA) associated vasculitis. Rituximab is likely to become the standard of care for many patients with ANCA disease. However, an individualized approach is needed to identify those who require more-intense or prolonged therapy.
authors.affiliation: Renal and Vascular Inflammation Section, Department of Medicine, Commonwealth Building, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK.
authors.forename: Ruth
authors.initials: R
authors.lastname: Tarzi
authors.forename: Charles
authors.initials: C
authors.lastname: Pusey
mesh_terms: D056648:Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / Q000188:drug therapy*; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D015337:Multicenter Studies as Topic; D016032:Randomized Controlled Trials as Topic; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab